Україна, Львів
+38 (050) 6956878
tourmanific@gmail.com

Norhinose. 50mcg/dose. 120 doses. Nasal Spray

Norhinose. 50mcg/dose. 120 doses. Nasal Spray

395.00

Treatment of seasonal and year-round allergic rhinitis in adults, adolescents and children from 6 years of age

SKU: nrhns120 Categories: ,

Description

Compound:

Each spray dose contains:

Mometasone furoate monohydrate 0.052 mg, which corresponds to the content of mometasone furoate 0.05 mg

Auxiliary components:

microcrystalline cellulose, carmellose sodium, glycerin, benzalkonium chloride, polysorbate 80, citric acid monohydrate, sodium citrate dihydrate, water for injection.

Properties:

GCS for intranasal use. It has anti-inflammatory and anti-allergic effect.

The mechanism of anti-allergic and anti-inflammatory action is due to the ability to inhibit the release of inflammatory mediators. It increases the production of lipomodulin, which is an inhibitor of phospholipase A, which causes a decrease in the release of arachidonic acid and, accordingly, inhibition of the synthesis of metabolic products of arachidonic acid – cyclic endoperoxides, prostaglandins.

Indications:

  • Treatment of seasonal and year-round allergic rhinitis in adults, adolescents and children from 6 years of age;
  • acute sinusitis or exacerbation of chronic sinusitis in adults (including the elderly) and adolescents from 12 years of age (as an adjunct therapeutic agent in antibiotic treatment);
  • acute rhinosinusitis with mild to moderate symptoms without signs of severe bacterial infection in patients aged 12 years and older;
  • prevention of seasonal allergic rhinitis of moderate and severe course in adults and adolescents from 12 years of age;
  • nasal polyposis, accompanied by a violation of nasal breathing and smell in adults (use after 18 years).

Dosage and administration:

Before using the first dose, shake the bottle well and press the spray pump 10 times (until a homogeneous spray is obtained).

Treatment of seasonal or year-round allergic rhinitis: for adults (including the elderly) and children over the age of 12, the recommended preventive and therapeutic dose of the drug is 2 injections (50 mcg each) in each nasal passage 1 time per day (total daily dose – 200 mcg). After achieving a therapeutic effect for maintenance therapy, it is advisable to reduce the dose to 1 injection in each nasal passage 1 time per day (total daily dose – 100 mcg).

If a decrease in the severity of the symptoms of the disease cannot be achieved using the drug at the recommended therapeutic dose, the daily dose can be increased to the maximum: 4 injections in each nasal passage 1 time per day (total daily dose – 400 mcg). After a decrease in the severity of symptoms of the disease, a dose reduction is recommended.

For children aged 6-11 years, the recommended therapeutic dose is 1 injection (50 mcg) in each nasal passage 1 time per day (total daily dose – 100 mcg).

Contraindications:

Hypersensitivity to the active substance or any inactive component of the drug. The drug should not be used in the presence of untreated localized infection involving the nasal mucosa. Due to the fact that corticosteroids have the ability to inhibit wound healing, patients who have recently had nasal surgery or had trauma should not use nasal corticosteroids until healing occurs.

Precautionary measures:

The drug should not be used in the presence of untreated local infection with the involvement of the nasal mucosa in the process.

Patients using corticosteroids can potentially be immunosuppressed and should be warned about the increased risk of infection through contact with persons with certain infectious diseases (such as chicken pox, measles), as well as the need to consult a doctor if such contact has taken place.

Side effects:

Infections and invasions: often – pharyngitis, infections of the upper respiratory tract.

From the immune system: unknown – hypersensitivity, including anaphylactic reactions, angioedema, bronchospasm and shortness of breath.

From the nervous system: often – headache.

On the part of the organ of vision: unknown – glaucoma, increased intraocular pressure, cataracts, blurred vision.

On the part of the respiratory system, chest organs and mediastinum: very often – epistaxis; often – epistaxis, burning sensation of the nasal mucosa, irritation of the nasal mucosa, ulceration of the nasal mucosa; unknown – perforation of the nasal septum.

From the gastrointestinal tract: often – irritation in the throat; unknown – violations of taste and smell.

Storage method:

Store at a temperature not exceeding 30 degrees.

 

Reviews

There are no reviews yet.

Be the first to review “Norhinose. 50mcg/dose. 120 doses. Nasal Spray”

Your email address will not be published.